The Crosstalk Between Microbiome, Cancer Immunology, and Immunotherapeutics: Myth or Reality

Tojjari, Alireza; Abushukair, Hassan; Saeed, Anwaar

doi:10.20944/preprints202209.0113.v1

Cited by 2 publications

(1 citation statement)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The estimated number of death is more than 7 lakh annually and according to recent data 661000 cases of hepatocellular carcinoma were recorded in 2018 and the incidence of HCC cases is expected to increase between 2018 and 2030 according to World Health Organisation (Abbas et al 2020). Rising HCC incidence cases occur in developing countries such as Sub-Sahara Africa, Southeast Asia, Asia, and China thus leading to a major concern in India (Tojjari et al 2023). The Risk factors for HCC include chronic HBV (hepatitis B virus) and HCV (hepatitis C virus) infections, autoimmune hepatitis, chronic alcohol use, diabetes mellitus, and obesity.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Multi-Epitope Vaccine Construction Using in Silico Strategies Against Hepatocellular Carcinoma

Shah,

Kumar

2023

jrtdd

View full text Add to dashboard Cite

Hepatocellular carcinoma is a chronic infection with progressing symptoms leading to an advanced stage with no effective therapy other than liver transplantation. Recent studies suggest that drugs such as sorafenib and lenvatinib however can provide some relief to the disease but have failed to provide complete protection. Thus considering all the facts, this study is conducted with an immunoinformatics approach targeting XIAP protein which is the key protein involved in the mechanism of Hepatocellular carcinoma (HCC) disease. The screening of the targeted genome sequence was performed to acquire CTL, HTL, and B-cell epitopes through different tools such as NetMHCPred, NetMHCPan, and BepiPred tool leading to the potential candidates for multi-epitope vaccine. Meanwhile, we also found the physiochemical, immunogenic and allergenicity scores of the filtered epitopes and these epitopes were found to be highly antigenic and immunogenic after validation of all the parameters. Meanwhile, the addition of adjuvant and linkers led to the formation of a strong vaccine construct and therefore the binding force between the final vaccine construct with protein through docking obtained was -905.7kcal/mol. Further in silico cloning and expression of the designed vaccine into the plasmid vector also depicted the good performance of designed vaccine thus making it a good choice for the novel vaccine. Henceforth, a potential therapeutic multi-epitope vaccine construct was found to be efficient and thus can be a promising vaccine that could induce strong immunity against Hepatocellular carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic Multi-Epitope Vaccine Construction Using in Silico Strategies Against Hepatocellular Carcinoma

Shah,

Kumar

2023

jrtdd

View full text Add to dashboard Cite

show abstract

Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment

Mir,

Albarqi,

Albalawi

et al. 2024

Metabolites

View full text Add to dashboard Cite

Background: The human digestive system contains approximately 100 trillion bacteria. The gut microbiota is an emerging field of research that is associated with specific biological processes in many diseases, including cardiovascular disease, obesity, diabetes, brain disease, rheumatoid arthritis, and cancer. Emerging evidence indicates that the gut microbiota affects the response to anticancer therapies by modulating the host immune system. Recent studies have explained a high correlation between the gut microbiota and breast cancer: dysbiosis in breast cancer may regulate the systemic inflammatory response, hormone metabolism, immune response, and the tumor microenvironment. Some of the gut bacteria are related to estrogen metabolism, which may increase or decrease the risk of breast cancer by changing the number of hormones. Further, the gut microbiota has been seen to modulate the immune system in respect of its ability to protect against and treat cancers, with a specific focus on hormone receptor-positive breast cancer. Probiotics and other therapies claiming to control the gut microbiome by bacterial means might be useful in the prevention, or even in the treatment, of breast cancer. Conclusions: The present review underlines the various aspects of gut microbiota in breast cancer risk and its clinical application, warranting research on individualized microbiome-modulated therapeutic approaches to breast cancer treatment.

show abstract

The Crosstalk Between Microbiome, Cancer Immunology, and Immunotherapeutics: Myth or Reality

Cited by 2 publications

References 74 publications

Therapeutic Multi-Epitope Vaccine Construction Using in Silico Strategies Against Hepatocellular Carcinoma

Therapeutic Multi-Epitope Vaccine Construction Using in Silico Strategies Against Hepatocellular Carcinoma

Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment

Contact Info

Product

Resources

About